COMMUNIQUÉS West-GlobeNewswire

Nonprofit Human Appeal Launches Winter Coat Drive Across US East Coast
07/11/2025
Human Appeal’s first U.S. domestic campaign aims to collect 3,500 coats for families in need FAIRFAX, Va., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Global humanitarian aid nonprofit Human Appeal has officially launched its [...]
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
07/11/2025
Net income of $5.9 million and $11.2 million for the three and nine months ended September 30, 2025, respectively Full-year revenue guidance revised to $115-118 million (from $118 - $128 million previously) due to [...]
Rapid Micro Biosystems Reports Third Quarter 2025 Financial Results; Announces Record Multi-System Customer Order and Raises Full-Year Revenue and System Placement Guidance
07/11/2025
Reports third quarter 2025 total revenue of $7.8 million , representing 3% growth compared to the third quarter of 2024. Third quarter 2025 recurring revenue, which includes consumables and annual service contracts, [...]
Sanuwave Announces Q3 FY2025 Financial Results
07/11/2025
Q3 2025 revenues were $11.5 million , up 22% from $9.4 million in Q3 2024. This represents the highest quarterly revenues in Company history. Q3 2025 gross margin was 77.9% , versus 75.5% in Q3 2024. GAAP Operating [...]
Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting
07/11/2025
Single ascending dose data show IMC-I109V has manageable safety profile and antiviral activity IMC-I109V is a bispecific T cell receptor targeting a peptide derived from HBsAg that is presented by HLA-A*02:01 on the [...]
Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
07/11/2025
Company Hosting Virtual KOL Panel Event Thursday, November 13th at 10:00 AM ET BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical [...]
Rivus Pharmaceuticals Announces New Data from Phase 2 M-ACCEL Trial of HU6 in MASH in Late-Breaker Oral Presentation at AASLD The Liver Meeting® 2025
07/11/2025
– Trial met primary endpoint, with statistically significant reductions in liver fat observed in all HU6 treatment groups – – In addition to robust liver-centric effects, HU6 resulted in fat-selective weight loss with [...]
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
07/11/2025
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase 3 data to be [...]
Communiqué de presse : ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique...
07/11/2025
ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique ; la [...]
Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies
07/11/2025
Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies Dr. Adrian Bot, a renowned biopharmaceutical founder and scientist, has joined [...]
Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing
07/11/2025
Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™ Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in antibiotic-resistant [...]
Vaxart to Host Upcoming Conference Calls
07/11/2025
Third quarter 2025 results conference call to be held on November 13 at 4:30 p.m. ET Stockholder fireside chat to be held on November 18 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- [...]
Major shareholder announcement
07/11/2025
Please read the full announcement in PDF Attachments 2025_47_Major_Shareholders_Announcement Novozymes B 05 November 2025_Final
Fangzhou, Novo Nordisk Launch Initiative for AI-Powered Diabetes and Weight Management Solutions at CIIE
07/11/2025
SHANGHAI, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, was invited to the “Boundless Care, New Beginnings” [...]
Research Update
07/11/2025
Scancell Holdings plc Scancell holds oral presentation of positive Phase 2 data on Immunobody ® iSCIB1+ in late-stage melanoma at SITC 2025 Data from SCOPE trial show a potential new benchmark i n efficacy, durability, [...]
Memo Therapeutics AG Presents Long Term Follow-Up Data from its Phase II SAFE KIDNEY Trial of Potravitug and Real World Data on the Challenges and Re-source Utilization of Managing Kidney Transplant Recipients at ASN Kidney Week Meeting
07/11/2025
PRESS RELEASE Memo Therapeutics AG Presents Long Term Follow-Up Data from its Phase II SAFE KIDNEY Trial of Potravitug and Real World Data on the Challenges and Resource Utilization of Managing Kidney Transplant [...]
Built for Peace of Mind: How HomeInherit Serves Seniors
07/11/2025
HomeInherit develops a senior-first home equity model built on clarity, safety, and community trust. HomeInherit Logo SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- HomeInherit, a senior-focused financial services [...]
React19 Launches “This Is Our Shot” Campaign as U.S. Vaccine Injury Victims Continue to Go Unheard and Uncompensated
07/11/2025
Patient-led nonprofit has already distributed $1.4 million in aid, challenging the federal government’s injury program SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- As the federal government’s Countermeasures Injury [...]
Kelyniam Global Renews Licensing Agreement with Finceramica, Unlocking Access to Valuable Pipeline Products
07/11/2025
CANTON, Conn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Kelyniam Global, Inc. (OTC: KLYG), a leading manufacturer of custom cranial and cranio-maxillofacial implants, today announced the renewal of its licensing agreement with [...]

Pages